Home › Funds › Prudential/PGIM › PGIM Jennison Health Sciences Fund
Fund family: Prudential/PGIM · Filed by PRUDENTIAL SECTOR FUNDS, INC. (CIK 352665) · SEC series S000004380
Share classes and tickers: PHLAX (C000012121), PHLCX (C000012123), PHLQX (C000165347), PHSZX (C000012124), PJHRX (C000110073)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 460 with, 11 against, 1 abstentions (not counted as with management); 2 items carried no recommendation. Shareholder proposals: 5 FOR, 7 AGAINST, 0 abstained, by the filing’s own vote-source field.
The same two figures as Prudential/PGIM’s manager page (236,459 ballot items across 88 funds and accounts), counted the same way for this fund.
| 2025-2026 | This fund | Items | Prudential/PGIM | Items |
|---|---|---|---|---|
| Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters) | 97.9% | 423 | 94.2% | 197,417 |
| Backed environmental and social shareholder proposals at US companies | n/a | 5 | 13.0% | 2,860 |
Each ballot item this fund voted is set against the votes of the other Prudential/PGIM funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted differently from most Prudential/PGIM funds on 11 items (3.7% of the 297 items where a comparison was possible).
| Company | Meeting | Item | This fund | Most Prudential/PGIM funds | Mgmt | Result |
|---|---|---|---|---|---|---|
| CVS Health Corporation | 2026-05-14 | Shareholder Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. | For | AGAINST — 16 of 17 Prudential/PGIM funds | Against | — |
| CVS Health Corporation | 2026-05-14 | Proposal to Approve the Company's 2026 Incentive Compensation Plan. | For | AGAINST — 16 of 18 Prudential/PGIM funds | For | — |
| Gilead Sciences, Inc. | 2026-04-30 | Shareholder To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. | For | AGAINST — 15 of 17 Prudential/PGIM funds | Against | Not approved, 13.1% support |
| CVS Health Corporation | 2026-05-14 | Say on Pay, a Proposal to Approve, on an Advisory Basis, the Company's Executive Compensation. | For | AGAINST — 17 of 20 Prudential/PGIM funds | For | — |
| UnitedHealth Group Incorporated | 2026-06-01 | Election of Directors. Charles Baker | Against | FOR — 12 of 16 Prudential/PGIM funds | Against | — |
| Celcuity Inc. | 2026-05-14 | To approve, on an advisory basis, named executive officer compensation. | For | AGAINST — 3 of 3 Prudential/PGIM funds | For | Passed (calculated), 95.1% support |
| Align Technology, Inc. | 2026-05-20 | Advisory Vote to Approve the Compensation of our Named Executive Officers | For | AGAINST — 6 of 9 Prudential/PGIM funds | For | Passed (calculated), 89.4% support |
| Enliven Therapeutics, Inc. | 2026-06-09 | To approve, in an advisory (non-binding) vote, the compensation of our named executive officers as disclosed in our proxy statement. | For | AGAINST — 3 of 4 Prudential/PGIM funds | For | Approved, 93.9% support |
| DENTSPLY SIRONA Inc. | 2026-06-02 | Approval, by non-binding vote, of the Company's executive compensation for 2025. | For | AGAINST — 3 of 4 Prudential/PGIM funds | For | Passed (calculated), 94.6% support |
| Enliven Therapeutics, Inc. | 2026-06-09 | To amend our amended and restated certificate of incorporation, as amended, to increase our authorized shares of common stock from 100,000,000 shares to 200,000,000 shares. | For | AGAINST — 2 of 3 Prudential/PGIM funds | For | Approved, 99.3% support |
| DENTSPLY SIRONA Inc. | 2026-06-02 | Election of Directors: Betsy D. Holden | For | AGAINST — 2 of 3 Prudential/PGIM funds | For | Passed (calculated), 86.0% support |
Download all 11 differences (CSV)
The same votes as “with management” above, by the sector of the company voted on. 71.6% of this fund’s 472 such votes could be given a sector; the other 134 (28.4%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 287 | 10 | 3.5% |
| Industrials | 34 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 257 | 0 |
| Audit-related | 53 | 0 |
| Say-on-Pay | 41 | 0 |
| Capital Structure | 40 | 0 |
| Compensation | 37 | 1 |
| Corporate Governance | 37 | 3 |
| Shareholder Rights and Defenses | 7 | 2 |
| Other Social Issues | 4 | 3 |
| Diversity, Equity, and Inclusion | 1 | 1 |
| Human Rights or Human Capital/workforce | 1 | 1 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| Eli Lilly and Company | May 4, 2026 | $333M | 10 | 2 |
| Merck & Co., Inc. | May 26, 2026 | $102M | 18 | 3 |
| UnitedHealth Group Incorporated | June 1, 2026 | $88M | 12 | 1 |
| Thermo Fisher Scientific Inc. | May 20, 2026 | $87M | 13 | 0 |
| argenx SE | November 18, 2025 | $75M | 1 | 0 |
| Gilead Sciences, Inc. | April 30, 2026 | $72M | 15 | 3 |
| Vertex Pharmaceuticals Incorporated | May 13, 2026 | $56M | 15 | 1 |
| argenx SE | May 6, 2026 | $56M | 12 | 0 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| June 1, 2026 | UnitedHealth Group Incorporated | If properly presented at the 2026 Annual Meeting of Shareholders, the shareholder proposal requesting the adoption of a policy to require any Board Chair to be independent. Shareholder proposal | For | Against |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | For | Against |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | For | Against |
| May 13, 2026 | Vertex Pharmaceuticals Incorporated | Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent. Shareholder proposal | Against | For |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | For | Against |
478 ballot items at 50 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, PGIM Jennison Health Sciences Fund (PHLAX) voted at 50 shareholder meetings of 49 companies, on 478 ballot items in all. Where management made a recommendation, the fund followed it on 97.5% of the items and voted against it 11 times. Its most frequent area of disagreement was corporate governance (3 of its votes against management). It voted on 12 shareholder proposals. It voted FOR the board's own proposals more often than Prudential/PGIM's funds as a whole (97.9% against 94.2%). It voted differently from most Prudential/PGIM funds on 11 items.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Prudential/PGIM’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.